Biospecimen and Pathology Core

项目摘要-生物质学和病理学核心B 皮肤癌Wistar/UPenn孢子的生物显微镜和病理核心的主要目的是 提供集中的设施，集中采购、加工、分析和分发 支持转译癌症研究，特别是黑色素瘤研究的正常组织。核心一直是 为前一供资期间的所有孢子项目提供有效资源，这些项目严重依赖组织， 并将继续为拟议的孢子项目提供必要的支持服务。这个 CORE将收集、储存和处理高质量和注释良好的生物标本(血液、新鲜和石蜡 肿瘤和正常组织)，使用按项目特定方式修改的SOP(目标1)。我们会 扩大和维护一个功能强大的多机构综合生物医学和临床数据库，其中包括 病理、治疗、复发和随访数据以及全面的获取和分布 与使用组织相关的数据。已有的数据库支持水平、垂直和交互 孢子协作(目标2)。我们将挑选和分发高质量的生物标本。我们已经开发出 从良性、原发和转移性肿瘤中选择、准备和分配注释良好的组织的程序； 根据每个项目的规格，从生物标本中提取DNA、RNA和蛋白质。分销是 由组织资源分配委员会(TRAC)制定的指导方针管理，以确保高效和 最大限度地利用组织，并为患者保密(目标3)。我们将为所有患者提供组织学检查 每个项目使用的生物标记物，组织处理和免疫组织化学，以及专家对 对组织进行的研究(目标4)。最后，我们将开发创新的研究分析和组织 针对每个项目的特定需求并促进临床效果研究的制备方法 (目标5)。

Project Summary – Biospecimen and Pathology Core B The primary objective of the Biospecimen and Pathology Core of the Wistar/UPenn SPORE in Skin Cancer is to provide a centralized facility focused on procurement, processing, analysis and distribution of malignant and normal tissue in support of translational cancer research, particularly melanoma research. The Core has been an effective resource for all SPORE projects in the prior funding period, which were heavily tissue-dependent, and will continue to provide essential support services for the proposed SPORE Projects moving forward. The Core will collect, store and process high-quality and well-annotated biospecimens (blood, fresh and paraffin embedded tissue) of tumor and normal tissue using SOPs modified in a Project specific manner (Aim 1). We will expand and maintain a functional multi-institutional integrated biospecimen and clinical database that includes pathological, treatment, recurrence, and follow-up data as well as comprehensive acquisition and distribution data associated with the use of tissue. The already existing database supports horizontal, vertical and inter- SPORE collaborations (Aim 2). We will select and distribute high quality biospecimens. We have developed procedures to select, prepare and distribute well-annotated tissues from benign, primary and metastatic tumors; DNA, RNA and proteins from biospecimens according to the specifications of each project. Distribution is governed by guidelines developed by the Tissue Resource Allocation Committee (TRAC) to ensure efficient and maximal use of tissue, and patient confidentiality (Aim 3). We will provide histological examination of all biospecimens used by each project, tissue processing and immunohistochemistry, and expert interpretation of studies performed on the tissue (Aim 4). Finally, we will develop innovative research assays and tissue preparation methods catering to the specific needs of each project and to facilitate clinically impactful research (Aim 5).